METTL1 and neoplasm: These findings suggest that METTL1 may be a pan-cancer immunotherapeutic response marker, and marker studies targeting METTL1 with expanded sample size and tumor type are important for monitoring the clinical efficacy of anti-PD1 immunotherapy.